Experts push for rabies vaccine in children before dog bites
Providing general immunity against rabies not only helps prevent deaths but also reduces the need for expensive rabies immunoglobulin (RIG), which is administered in addition to the standard post-bite vaccine. While previously seen as an excessive measure, the surge in rabies cases and the high cost of post-exposure treatment have made PrEP a necessary intervention.
Dog bite cases in Kerala have seen a dramatic rise - from 60,000 in 2013 to over 3.16 lakh in 2024. Human fatalities have also increased, with 14 rabies deaths reported so far this year, and an annual toll of 20-25 deaths in recent years. Children remain the most affected. Globally, rabies claims around 59,000 lives annually, with 18,000-20,000 of those in India. Of these, nearly 40% are children.
'Children are most vulnerable. Many have died even after receiving the vaccine post-bite due to the challenging nature of the bites,' said Dr Riaz I, president of the IAP Kerala Chapter. 'We recommend PrEP for school-going children to prevent such tragedies.' Dr Riaz also pointed out the difficulty of administering rabies serum in sensitive bite locations like eyes, underlining the advantage of pre-exposure vaccination.
The KGMOA has urged the state to form a task force to implement a universal PrEP programme, starting with children.
'Over 35% of dog bite victims are children. We must prioritise them,' said Dr Sunil P K, KGMOA president.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 days ago
- Time of India
IAP launches nationwide initiative on paediatric allergic disorders from Nagpur
1 2 Nagpur: The Indian Academy of Paediatrics (IAP), under the leadership of its national president 2025, Dr Vasant Khalatkar — who hails from Nagpur — launched a nationwide initiative to tackle the growing but often neglected issue of paediatric allergic disorders. "Allergic diseases are not just about sneezing or itching — they silently steal away a child's happiness, confidence, and health," said Dr Khalatkar, emphasising the urgent need for awareness. "We are not just treating sneezes and rashes — we are protecting childhood," he added, calling on parents, teachers, and paediatricians to take early action. With 20-30% of Indian children now estimated to suffer from allergies such as asthma, allergic rhinitis, food allergies, and atopic dermatitis, the IAP's campaign comes at a crucial time. Rapid urbanisation, climate change, air pollution, and shifting diets are further aggravating the problem. IAP's chapter of allergy and applied immunology will drive this movement from Nagpur to all corners of the country. "India is witnessing a silent surge in allergic disorders," Dr Khalatkar said. "Our mission is to standardise diagnosis, enhance paediatric training, and build community-level awareness so that no child suffers silently." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Storage running out on your Mac? Space Lens will show you why MacPaw Read More Undo The IAP's campaign not only aims at clinical improvement but also focuses on reducing the emotional and social impact of allergies on young lives. The academy has appealed to schools, paediatricians, parents, and policymakers to work hand-in-hand to identify symptoms early, ensure proper care, and create safe, allergy-informed environments. This nationwide effort, rooted in Nagpur leadership, marks a major step towards ensuring that childhood allergies are no longer ignored but addressed with seriousness, empathy, and science.
Time of India
6 days ago
- Time of India
Lifesavers in the making: Schoolkids get lessons in IAP-CPR skills at AIIMS-Bhopal
Bhopal: AIIMS Bhopal is conducting a CPR training sessions for schoolstudents as part of IAP-CPR Awareness Month. The event that will conclude on During July 28, aims to educate students about essential emergency response techniques, according to a press release here on Saturday. AIIMS Bhopal's paediatrics and emergency medicine specialists conducted practical CPR training for students from Classes 9-12 at a private school in Baghmugaliya. The programme focuses on preparing students to become competent first responders during their school years. Child specialist Dr Girish Chandra Bhatt emphasised that CPR knowledge is essential, noting that over 70% of cardiac arrests occur outside medical facilities. Students received instruction in vital techniques including chest compressions, rescue breathing, and choking responses through Heimlich manoeuvre, back blows, and chest thrusts. Dr Bhupeshwari Patel and Dr Babu Lal Soni, along with residents and nurses, supervised students practising on specialised training models. Students engaged in practical demonstrations, question sessions, and emergency scenario discussions, making the training accessible. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo The school principal commended the programme as "a game-changer in preparing students for real-world emergencies." Looking ahead to IAP National CPR Day on July 21st, Dr Bhatt stated, "When children are trained in CPR and emergency response, we build a society that is not only more informed but also more compassionate and ready to act in critical situations."
The Hindu
15-07-2025
- The Hindu
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug
Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused on HIV medicines and majority owned by GSK with Pfizer and Shionogi as shareholders, and Medicines Patent Pool (MPP) extending their voluntary licensing agreement to enable access to long-acting injectable HIV treatment. It builds on the voluntary license for CAB LA for HIV pre-exposure prophylaxis (PrEP). The announcement, on extending their agreement, comes in the wake of an updated guidance from World Health Organization (WHO) recommending long-acting injectable cabotegravir + rilpivirine as an HIV treatment option. Existing licensees Aurobindo, Cipla and Viatris will consequently be able to develop, manufacture and supply generic versions of CAB LA, for use in combination with long-acting rilpivirine, for the treatment of HIV-1 infection in adults and adolescents weighing at least 35kg subject to required regulatory approvals being obtained, Aurobindo Pharma said on Tuesday. Vice chairman and MD of Aurobindo Pharma K. Nithyananda Reddy said the company remains committed to leveraging its global supply capabilities to make the vital combination long-acting injection therapy widely available and affordable. The consideration by ViiV and MPP to include the private market in royalty-bearing countries is a critical step toward expanding access across both public and private sectors, he said.
